Analysts: Recovery Will Benefit GM and 3 More Research Notes to Check Out
General Motors (NYSE:GM): Based on expectations that shareholders will benefit from a steady recovery in the North America vehicle cycle, disciplined capital allocation, record earnings, and increasing cash returns, Sterne Agee has raised its price target on the shares, from $40 to $46, and keeps a Buy rating on the stock.
AIG (NYSE:AIG): AIG has the option to cancel its sale of 80 percent of ILFC to a Chinese consortium after a deposit deadline was missed, although Wells Fargo doesn’t expect the firm to cancel the deal. The firm keeps a Market Perform rating on the company, and notes that the closing of the deal may be later or may not happen, which could impact AIG’s capital return plans.
Guess Inc. (NYSE:GES): Solid Q1 results have led Brean Capital to raise its price target on Guess from $28 to $37, as it sees Guess’s guidance as conservative, easy comps, higher margins, and the potential for higher top and bottom line upside. Shares are rated at Buy.
Myriad Genetics (NASDAQ:MYGN): Jefferies has brought shares of Myriad down from Buy to Hold, after assuming coverage of the stock and citing valuation concerns. Price target is $31.